Pharmacotherapy of Vulvovaginal Candidiasis According to Pharmacoepidemiology Data and Evidence-Based Medicine

Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(1):34-47

Journal article


Approximately 75% of women experience at least one episode of acute vulvovaginal candidiasis during their life. In the 1980-90s, almost two-fold increase in fungal vaginitis was observed with increase in number of cases caused by non-albicans strains Candida. Despite the number of available antifungals, rate of treatment failure remains relatively high and lead to spread of the resistant strains and transformation of the disease to the chronic and recurrent forms. Currently, there are no data on clinical equivalence of the original and generic antifungal agents. Adequate clinical trials focused on the clinical efficacy assessment and eradication rates in the treatment with the different antifungals may help to improve the quality of treatment. This paper is an attempt to identify current trends in epidemiology and treatment of vulvovaginal candidiasis according to evidence-based medicine.

0 Abstract
0 Crossref citations